Comparative study on mannose 6-phosphate residue contents of recombinant lysosomal enzymes

Molecular Genetics and Metabolism

Volumn 111, Issue 3, 2014, Pages 369-373

  Togawa, Tadayasu ^a   Takada, Masaru ^a   Aizawa, Yoshiaki ^a   Tsukimura, Takahiro ^a   Chiba, Yasunori ^b   Sakuraba, Hitoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Enzyme replacement therapy; Lysosomal disease; Lysosomal enzyme; Mannose 6 phosphate

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA N ACETYLGALACTOSAMINIDASE; GLYCOPROTEIN; IDURONATE 2 SULFATASE; IMIGLUCERASE; LARONIDASE; LYSOSOME ENZYME; MANNOSE 6 PHOSPHATE; RECOMBINANT ENZYME; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; ALPHA GALACTOSIDASE; HYDROLASE; ISOENZYME; MANNOSE PHOSPHATE; MANNOSE-6-PHOSPHATE; RECOMBINANT PROTEIN; SOMATOMEDIN B RECEPTOR;

ARTICLE; COMPARATIVE STUDY; DERIVATIZATION; ENZYME ASSAY; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUNTER SYNDROME; HURLER SYNDROME; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; CHEMISTRY; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; LYSOSOME; METABOLISM;

ALPHA-GALACTOSIDASE; ENZYME REPLACEMENT THERAPY; HUMANS; HYDROLASES; ISOENZYMES; LYSOSOMES; MANNOSEPHOSPHATES; RECEPTOR, IGF TYPE 2; RECOMBINANT PROTEINS;

EID: 84894423242     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.12.296     Document Type: Article

References (37)

1. Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow G.C., Borowski M., Loveday K., Anderson T., Gillespie F., Oliver K.L., Jeffries N.O., Doo E., Liang T.J., Kreps C., Gunter K., Frei K., Crutchfield K., Selden R.F., Brady R.O. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:365-370.
2. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 2001, 68:711-722.
3. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 2001, 345:9-16.
4. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 3733-3774. McGraw-Hill, New York, USA. Eighth edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
5. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., McDonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., Van der Ploeg A., Clancy J.P., Parini R., Morin G., Beck M., De la Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
6. Winkel L.P., Van den Hout J.M., Kamphoven J.H., Disseldorp J.A., Remmerswaal M., Arts W.F., Loonen M.C., Vulto A.G., Van Doorn P.A., De Jong G., Hop W., Smit G.P., Shapira S.K., Boer M.A., Van Diggelen O.P., Reuser A.J., Van der Ploeg A.T. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann. Neurol. 2004, 55:495-502.
7. Hirschhorn R., Reuser R.J.J. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. The Metabolic and Molecular Bases of Inherited Disease 2001, 3389-3420. McGraw-Hill, New York, USA. eighth edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
8. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 2001, 344:182-188.
9. Neufeld E.F., Muenzer J. The mucopolysaccharidosis. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-3452. McGraw-Hill, New York, USA. Eighth edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
10. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 2006, 8:465-473.
11. Harmatz P., Giugliani R., Schwatz I.V., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Ketteridge D., Hopwood J.J., Plecko B., Steiner R., Whitley C.B., Kaplan P., Yu Z.F., Swiedler S.J., Decker C. MPS VI Study Group. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol. Genet. Metab. 2008, 94:469-475.
12. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., Parker C., Schiffmann R., Hill S.C., Brady R.O. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 1995, 122:33-39.
13. Gonzalez D.E., Turkia H.B., Lukina E.A., Kisinovsky I., Dridi M.-F.B., Elstein D., Zahrieh D., Crombez E., Bhirangi K., Barton N.W., Zimran A. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study. Am. J. Hematol. 2013, 88:166-171.
14. Zimran A., Brill-Almon E., Chertkoff R., Petakov M., Blanco-Favela F., Muñoz E.T., Solorio-Meza S.E., Amato D., Duran G., Giona F., Heitner R., Rosenbaum H., Giraldo P., Mehta A., Park G., Phillips M., Elstein D., Altarescu G., Szleifer M., Hashmueli S., Aviezer D. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011, 118:5767-5773.
15. Beutler E., Grabowski G.A. Gaucher disease. The Metabolic and Molecular Bases of Inherited Disease 2001, 3635-3668. McGraw-Hill, New York, USA. Eighth edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
16. Kornefeld S., Sly W.S. I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization. The Metabolic and Molecular Bases of Inherited Disease 2001, 3469-3482. McGraw-Hill, New York, USA. Eighth edition. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
17. Doebber T.W., Wu M.S., Bugianesi R.L., Ponpipom M.M., Furbish F.S., Barranger J.A., Brady R.O., Shen T.Y. Enchanced macrophage uptake of synthetically glycosylated human placental β-glucocerebrosidase. J. Biol. Chem. 1982, 257:2193-2199.
18. Zhu Y., Jiang J.L., Gumlaw N.K., Zhang J., Bercury S.D., Ziegler R.J., Lee K., Kudo M., Canfield W.M., Edmunds T., Jiang C., Mattaliano R.J., Cheng S.H. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 2009, 17:954-963.
19. Zhou Q., Stefano J.E., Harrahy J., Finn P., Avila L., Kyazike J., Wei R., Van Patten S.M., Gotschall R., Zheng X., Zhu Y., Edmunds T., Pan C.Q. Strategies for neoglycan conjugation to human acid α-glucosidase. Bioconjug. Chem. 2011, 22:741-751.
20. Tajima Y., Kawashima I., Tsukimura T., Sugawara K., Kuroda M., Suzuki T., Togawa T., Chiba Y., Jigami Y., Ohno K., Fukushige T., Kanekura T., Itoh K., Ohashi T., Sakuraba H. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 2009, 85:569-580.
21. Zhou Q., Kyazike J., Edmunds T., Higgins E. Mannose 6-phosphate quantitation in glycoproteins using high-pH anion-exchange chromatography with pulsed amperometric detection. Anal. Biochem. 2002, 306:163-170.
22. Takashiba M., Chiba Y., Arai E., Jigami Y. Analysis of mannose-6-phosphate labeled with 8-aminopyrene-1,3,6-trisulfonate by capillary electrophoresis. Anal. Biochem. 2004, 332:196-198.
23. Lee K., Jin X., Zhang K., Copertino L., Andrews L., Baker-Malcolm J., Geagan L., Qiu H., Seiger K., Barngrover D., McPherson J.M., Edmunds T.A. Biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003, 13:305-313.
24. McVie-Wylie A.J., Lee K.L., Qiu H., Jin X., Do H., Gotschall R., Thurberg B.L., Rogers C., Raben N., O'Callaghan M., Canfield W., Andrews L., McPherson J.M., Mattaliano R.J. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol. Genet. Metab. 2008, 94:448-455.
25. Van Patten S.M., Hughes H., Huff M.R., Piepenhagen P.A., Waire J., Qiu H., Ganesa C., Reczek D., Ward P.V., Kutzko J.P., Edmunds T. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 2007, 17:467-478.
26. Takemoto H., Hase S., Ikenaka T. Microquantitative analysis of neutral and amino sugars as fluorescent pyridylamino derivatives by high-performance liquid chromatography. Anal. Biochem. 1985, 145:245-250.
27. Akeboshi H., Chiba Y., Kasahara Y., Takashiba M., Takaoka Y., Ohsawa M., Tajima Y., Kawashima I., Tsuji D., Itoh K., Sakuraba H., Jigami Y. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta. Appl. Environ. Microbiol. 2007, 73:4805-4812.
28. White J.T., Martell A.L., Prince W.S., Boyer R., Crockett L., Cox C., Tuyl A.V., Aguilera A., Foehr E. Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase). AAPS J. 2008, 10:439-449.
29. Marchesan D., Cox T.M., Deegan P.B. Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease. J. Inherit. Metab. Dis. 2012, 35:1107-1117.
30. Prabakaran T., Nielsen R., Satchell S.C., Mathieson P.W., Feldt-Rasmussen U., Sørensen S.S., Christensen E.I. Mannose 6-phosphate receptor and sortilin mediated endocytosis of α-galactosidase A in kidney endothelial cells. PLoS One 2012, 7:e39975.
31. Prabakaran T., Nielsen R., Larsen J.V., Sørensen S.S., Feldt-Rasmussen U., Saleem M.A., Petersen C.M., Verroust P.J., Christensen E.I. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease. PLoS One 2011, 6:e25065.
32. Zhu Y., Li X., Kyazike J., Zhou Q., Thurberg B.L., Raben N., Mattaliano R.J., Cheng S.H. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in Pompe mice. J. Biol. Chem. 2004, 279:50336-50341.
33. Koeberl D.D., Luo X., Sun B., McVie-Wylie A., Dai J., Li S., Banugaria S.G., Chen Y.T., Bali D.S. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol. Genet. Metab. 2011, 103:107-112.
34. 3H]hexosaminidase B by insulin-like growth factor-II in rat C6 glial cells. Mol. Cell. Endocrinol. 1992, 90:147-153.
35. Raben N., Danon M., Gilbert A.L., Dwivedi S., Collins B., Thurberg B.L., Mattaliano R.J., Nagaraju K., Plotz P.H. Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 2003, 80:159-169.
36. Wenk J., Hille A., von Figura K. Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem. Int. 1991, 23:723-731.
37. Funk B., Kessler U., Eisenmenger W., Hansmann A., Kolb H.J., Kiess W. Expression of the insulin-like growth factor-II/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy. J. Clin. Endocrinol. Metab. 1992, 75:424-431.